International symposium in Kiel on the immune metabolism of chronic inflammatory diseases
Researchers from several countries discussed how metabolic processes influence the immune system and thus chronic inflammatory processes at the symposium of the TRY-IBD joint project.
From September 12 - 13, 2024, scientists met for the international symposium of the junior collaborative project “TRY-IBD”. The project, which has been funded by the Federal Ministry of Education and Research since 2019, will reach the end of its funding period in 2024. “The aim of the symposium at the end of the funding period was to discuss where the field of immunometabolism is heading in the future and what concrete possibilities exist for further development,” says Prof. Konrad Aden, project head of TRY-IBD. The research focus of the project is an important part of the research program of the Cluster of Excellence “Precision Medicine in Chronic Inflammation” (PMI).
Around 60 participants attended the symposium at the Kiel Science Center to discuss the latest findings in the field of immunometabolism. Speakers from Germany, Luxembourg, France, Denmark, Italy, Israel and Switzerland provided valuable input on various metabolic processes that influence the immune system and thus chronic inflammatory diseases via different pathways.
A poster session with awards for the best three works topped off the program.
The members of TRY-IBD can look back on a fruitful exchange during the symposium and a successful collaboration in the project.
About TRY-IBD:
TRY-IBD is a junior research network funded by the Federal Ministry of Education and Research since 2019. The aim of the members of TRY-IBD is to research tryptophan-controlled immunometabolism as a new pathophysiological principle in chronic inflammatory bowel disease (IBD). The project has also been integrated into the “eMED” funding initiative to promote systems medicine approaches. The total funding amount is € 3.5 million.
Additional information on TRY-IBD.
